Neil T Chen

US Patent:

D559404, Jan 8, 2008

Filed:

Nov 8, 2006

Appl. No.:

29/268466

Inventors:

Neil Taicheng Chen - Albuquerque NM, US

Assignee:

C & H Rio Rancho Holding LLC - Albuquerque NM

International Classification:

2502

US Classification:

D25 48

US Patent:

50968920, Mar 17, 1992

Filed:

May 27, 1988

Appl. No.:

7/199620

Inventors:

Moses J. Folkman - Brookline MA
Neil T. Chen - Newton Center MA
Elias J. Corey - Cambridge MA

Assignee:

The Children's Medical Center Corporation - Boston MA
President and Fellows of Harvard College - Cambridge MA

International Classification:

A61K 31235
A61K 3156
A61K 3157
A61K 31725

US Classification:

514 56

Abstract:

Anigiogenesis is controlled by administering to a mammal an effective amount of an inhibitor of arylsulfatase. Preferably, the arylsulfatase inhibitor is administered in a pharmaceutically acceptable vehicle in combination with an angiostatic steroid and (optionally) heparin (by which term we include all forms and fragments of heparin having the desired angiostatic activity). Hydrocortisone is one specifically preferred steroid. The preferred arylsulfatase inhibitor is a carboxylic acid ester or a sulfuric acid ester of a benzylic alcohol, most preferably the esters defined more particularly below. The arylsulfatase inhibitor is preferably administered locally to the tissue experiencing undesired angiogenesis. Arylsulfatase inhibitor and an angiostatic steroid are included in a pharmaceutically acceptable vehicle, preferably also with heparin, to yield an angiostatic thereapeutic composition. Also, coagulation of blood is inhibited by adding a composition comprising an arylsulfatase inhibitor and heparin to the blood.